| Added by | standudu |
|---|---|
| Group name | EquipeCTCS |
| Item Type | Journal Article |
| Title | Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016 |
| Creator | Deluche et al. |
| Author | Elise Deluche |
| Author | Alison Antoine |
| Author | Thomas Bachelot |
| Author | Audrey Lardy-Cleaud |
| Author | Etienne Brain |
| Author | Marc Debled |
| Author | William Jacot |
| Author | Marie Ange Mouret-Reynier |
| Author | Anthony Goncalves |
| Author | Florence Dalenc |
| Author | Anne Patsouris |
| Author | Jean Marc Ferrero |
| Author | Christelle Levy |
| Author | Veronique Lorgis |
| Author | Laurence Vanlemmens |
| Author | Claudia Lefeuvre-Plesse |
| Author | Simone Mathoulin-Pelissier |
| Author | Thierry Petit |
| Author | Lionel Uwer |
| Author | Christelle Jouannaud |
| Author | Marianne Leheurteur |
| Author | Magali Lacroix-Triki |
| Author | Coralie Courtinard |
| Author | Mathieu Robain |
| Author | Suzette Delaloge |
| Abstract | AIM: Real-world data inform the outcome comparisons and help the development of new therapeutic strategies. To this end, we aimed to describe the full characteristics and outcomes in the Epidemiological Strategy and Medical Economics (ESME) cohort, a large national contemporary observational database of patients with metastatic breast cancer (MBC). METHODS: Women aged ?18 years with newly diagnosed MBC and who initiated MBC treatment between January 2008 and December 2016 in one of the 18 French Comprehensive Cancer Centers (N = 22,109) were included. We assessed the full patients' characteristics, first-line treatments, overall survival (OS) and first-line progression-free survival, as well as updated prognostic factors in the whole cohort and among the 3 major subtypes: hormone receptor positive and HER2-negative (HR+/HER2-, n = 13,656), HER2-positive (HER2+, n = 4017) and triple-negative (n = 2963) tumours. RESULTS: The median OS of the whole cohort was 39.5 months (95% confidence interval [CI], 38.7-40.3). Five-year OS was 33.8%. OS differed significantly between the 3 subtypes (p < 0.0001) with a median OS of 43.3 (95% CI, 42.5-44.5) in HR+/HER2-; 50.1 (95% CI, 47.6-53.1) in HER2+; and 14.8 months (95% CI, 14.1-15.5) in triple-negative subgroups, respectively. Beyond performance status, the following variables had a constant significant negative prognostic impact on OS in the whole cohort and among subtypes: older age at diagnosis of metastases (except for the triple-negative subtype), metastasis-free interval between 6 and 24 months, presence of visceral metastases and number of metastatic sites ? 3. CONCLUSIONS: The ESME program represents a unique large-scale real-life cohort on MBC. This study highlights important situations of high medical need within MBC patients. DATABASE REGISTRATION: clinicaltrials.gov Identifier NCT032753. |
| Publication | European Journal of Cancer (Oxford, England: 1990) |
| Volume | 129 |
| Pages | 60-70 |
| Date | 2020-04 |
| Journal Abbr | Eur J Cancer |
| Language | eng |
| DOI | 10.1016/j.ejca.2020.01.016 |
| ISSN | 1879-0852 |
| Library Catalog | PubMed |
| Extra | PMID: 32135312 |
| Tags | Abdominal Neoplasms, Adolescent, Adult, Age Factors, Aged, Bone Neoplasms, Brain Neoplasms, Breast, Breast Neoplasms, clinic, Disease-Free Survival, Female, France, HER2, Humans, Kaplan-Meier Estimate, Lymphatic Metastasis, Middle Aged, Prognosis, Progression-Free Survival, Real life, Receptor, ErbB-2, Receptors, Estrogen, Receptors, Progesterone, Retrospective Studies, Skin Neoplasms, Subtypes, Young Adult |
| Date Added | 2023/11/14 - 15:13:22 |
| Date Modified | 2023/11/14 - 15:52:49 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
